Market capitalization | $813.24m |
Enterprise Value | $578.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 22.59 |
EV/Sales (TTM) EV/Sales | 2.01 |
P/S ratio (TTM) P/S ratio | 2.83 |
P/B ratio (TTM) P/B ratio | 1.92 |
Revenue growth (TTM) Revenue growth | 71.67% |
Revenue (TTM) Revenue | $287.59m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
9 Analysts have issued a Castle Biosciences Inc forecast:
9 Analysts have issued a Castle Biosciences Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 288 288 |
72%
72%
|
|
Gross Profit | 225 225 |
91%
91%
|
|
EBITDA | -2.67 -2.67 |
97%
97%
|
EBIT (Operating Income) EBIT | -16 -16 |
84%
84%
|
Net Profit | -3.10 -3.10 |
97%
97%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Head office | United States |
CEO | Derek Maetzold |
Employees | 610 |
Founded | 2007 |
Website | www.castlebiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.